STUDY OF TEMOZOLOMIDE IN TREATMENT OF GLIOBLASTOMA MULTIFORME AT FIRST RELAPSE

替莫唑胺治疗初次复发多形性胶质母细胞瘤的研究

• 批准号: 6274742
• 负责人: HARRY S GREENBERG
• 金额: $ 2.15万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274742
• 关键词: clinical research; drug adverse effect; drug screening /evaluation; glioblastoma multiforme; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; quality of life; temozolomide

A randomized open label phase II study of Temozolomide and reference agent Procarbazine in the treatment of patients with glioblastoma multiforme at first relapse after surgery, external beam chemotherapy and at most one chemotherapy regimen. Efficacy will defined as six month progression free survival. Secondary measures will be quality of life and survival. Toxicity will be carefully monitored.

一项替莫唑胺和参比药物的随机、开放标签、II期研究 丙卡巴肼治疗胶质母细胞瘤 术后第一次复发多形性，外照射化疗 和至多一种化疗方案。 疗效将定义为6 月无进展生存期。次要措施将是质量 生命和生存。 将仔细监测毒性。